» Articles » PMID: 38856741

Remineralization Rate of Lytic Lesions of the Spine in Multiple Myeloma Patients Undergoing Radiation Therapy

Abstract

Study Design: Retrospective cohort study.

Objective: In general, Multiple Myeloma (MM) patients are treated with systemic therapy including chemotherapy. Radiation therapy can have an important supportive role in the palliative management of MM-related osteolytic lesions. Our study aims to investigate the degree of radiation-induced remineralization in MM patients to gain a better understanding of its potential impact on bone mineral density and, consequently, fracture prevention. Our primary outcome measure was percent change in bone mineral density measured in Hounsfield Units (Δ% HU) between pre- and post-radiation measurements, compared to non-targeted vertebrae.

Methods: We included 119 patients with MM who underwent radiotherapy of the spine between January 2010 and June 2021 and who had a CT scan of the spine at baseline and between 3-24 months after radiation. A linear mixed effect model tested any differences in remineralization rate per month (β) between targeted and non-targeted vertebrae.

Results: Analyses of CT scans yielded 565 unique vertebrae (366 targeted and 199 non-targeted vertebrae). In both targeted and non-targeted vertebrae, there was an increase in bone density per month (β = .04; = .002) with the largest effect being between 9-18 months post-radiation. Radiation did not cause a greater increase in bone density per month compared to non-targeted vertebrae (β = .67; = .118).

Conclusion: Our results demonstrate that following radiation, bone density increased over time for both targeted and non-targeted vertebrae. However, no conclusive evidence was found that targeted vertebrae have a higher remineralization rate than non-targeted vertebrae in patients with MM.

References
1.
Spanoudakis E, Papoutselis M, Terpos E, Dimopoulos M, Tsatalas C, Margaritis D . Overexpression of RANKL by invariant NKT cells enriched in the bone marrow of patients with multiple myeloma. Blood Cancer J. 2016; 6(11):e500. PMC: 5148055. DOI: 10.1038/bcj.2016.108. View

2.
Lang K, Konig L, Bruckner T, Forster R, Sprave T, Schlampp I . Stability of Spinal Bone Lesions in Patients With Multiple Myeloma After Radiotherapy-A Retrospective Analysis of 130 Cases. Clin Lymphoma Myeloma Leuk. 2017; 17(12):e99-e107. DOI: 10.1016/j.clml.2017.09.005. View

3.
Lee Y, Heo W, Nam J, Jeung Y, Bae J . The combination of ionizing radiation and proteasomal inhibition by bortezomib enhances the expression of NKG2D ligands in multiple myeloma cells. J Radiat Res. 2018; 59(3):245-252. PMC: 5967576. DOI: 10.1093/jrr/rry005. View

4.
Sonmez M, Akagun T, Topbas M, Cobanoglu U, Sonmez B, Yilmaz M . Effect of pathologic fractures on survival in multiple myeloma patients: a case control study. J Exp Clin Cancer Res. 2008; 27:11. PMC: 2438338. DOI: 10.1186/1756-9966-27-11. View

5.
Chandra A, Lin T, Tribble M, Zhu J, Altman A, Tseng W . PTH1-34 alleviates radiotherapy-induced local bone loss by improving osteoblast and osteocyte survival. Bone. 2014; 67:33-40. PMC: 4154509. DOI: 10.1016/j.bone.2014.06.030. View